Oppenheimer analyst Jay Olson lowered his price target for Intercept to $170 from $175 saying that while he continues to view the selloff in the shares post REGENERATE Phase 3 as an overreaction, his DCF and SOTP valuations support a $170 valuation. The analyst remains confident that the company has the first approvable registrational study in NASH for a drug that is already approved for PBC. Olson reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.